Stellar outlines strategy at Cowen conference; gets Chinese patent
Upcoming milestones for Stellar Pharmaceuticals (OTCBB:SLXCF) provide for near-and mid-term investment triggers, President and CEO, Peter Riehl, said in a presentation at the SG Cowen healthcare conference in Boston.
Stellar, which is only one of three Canadian companies presenting at the Cowen conference, is aggressively expanding its global out-licensing programs for its two lead products – Uracyst for the treatment of interstitial cystits/painful bladder syndrome (IC/PBS) and NeoVisc for osteoarthritis.
At the same time, Stellar is working with its U.S. partner for Uracyst, Watson Pharmaceuticals (NYSE:WPI), towards FDA approval and subsequent U.S. commercial launch. It is also on the hunt to acquire new products or companies.
Industry sources say Stellar’s appearance at the Cowan conference and its arrival on investors’ radar screens reflects the fact that Uracyst is gaining a competitive advantage over other less effective treatments for IC/PBS. New research suggests that chondroitin sulphate, the active ingredient in Uracyst, repairs defects in the bladder wall, known as the GAG layer, and re-establishes the bladder barrier function.
A webcast archive of Mr. Riehl’s presentation at the Cowen conference can be accessed here.
Separately, Stellar reported that the Chinese Patent Office has allowed a patent on Uracyst, which covers pharmaceutical compositions that comprise the greater and superior dosage sizes of chondroitin sulfate, and the use of those compositions for the treatment of IC/PBS. Once issued, the patent will expire on Feb. 18, 2024.
“With Uracyst patents already issued in Canada, the U.S. and Australia, and with numerous additional international patents pending, the Chinese patent expands Stellar’s already formidable intellectual property estate,” Mr. Riehl said in a statement.
“Along with our Shanghai-based marketing and distribution partner, Shanghai Ya Jun Medical Equipment Co. Ltd., we are very excited about commercially launching Uracyst in this important market pending Chinese State Food and Drug Administration approval,” he added.